Keyphrases
Triple-negative Breast Cancer
100%
Population-based Study
100%
Overall Survival
66%
Tumor Grade
33%
Male Patients
33%
Histology
22%
Statistical Significance
22%
Management Strategy
22%
T Stage
22%
Breast Cancer Cases
22%
Prognostic Factors
22%
Treatment Strategy
22%
Tumor Stage
22%
Male Breast Cancer
22%
Partial Mastectomy
22%
Total Mastectomy
22%
Risk Factors
11%
Retrospective Cohort Study
11%
Tumor
11%
Breast Cancer Patients
11%
Epidermal Growth Factor Receptor
11%
Worse Outcome
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Advanced Disease
11%
Malignancy
11%
Advanced Age
11%
Screening Guidelines
11%
Progesterone Receptor
11%
Estrogen Receptor
11%
Optimal Treatment
11%
High Stage
11%
Surveillance Epidemiology
11%
National Cancer Institute
11%
Survival Disparities
11%
Several Variables
11%
Stage at Diagnosis
11%
Disease Stage
11%
End Results Program
11%
Insurance Status
11%
Small Populations
11%
Nodal Status
11%
All-male
11%
Overall Survival Benefit
11%
Future Management
11%
Male Cohort
11%
Surgical Treatment Strategy
11%
LESS Surgery
11%
Diagnosis Strategy
11%
Medicine and Dentistry
Triple Negative Breast Cancer
100%
Overall Survival
77%
Neoplasm
44%
Cancer Staging
22%
Prognostic Factor
22%
Quadrantectomy
22%
Male Breast Cancer
22%
Simple Mastectomy
22%
Malignant Neoplasm
11%
Surgery
11%
Cancer
11%
Disease
11%
Retrospective Cohort Study
11%
Estrogen Receptor
11%
Progesterone Receptor
11%
Population Research
11%
Surveillance, Epidemiology, and End Results
11%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
11%
Population Size
11%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Overall Survival
77%
Neoplasm
44%
Cancer Staging
22%
Male Breast Cancer
22%
Cohort Study
11%
Disease
11%
Malignant Neoplasm
11%
Progesterone Receptor
11%
Estrogen Receptor
11%
Population Study
11%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
11%